Back to Search
Start Over
[Caution with the use of dexamethasone in patients with COVID-19 in its initial phases].
- Source :
-
Revista clinica espanola [Rev Clin Esp] 2021 Dec; Vol. 221 (10), pp. 592-595. Date of Electronic Publication: 2021 Mar 06. - Publication Year :
- 2021
-
Abstract
- Introduction: The effect of dexamethasone in the initial phase of infection by SARS-CoV-2 and its influence on COVID-19 is not well defined. We describe clinical-radiological characteristics, the cytokine storm parameters, and the clinical evolution of a series of patients treated with dexamethasone in the disease's initial phase.<br />Method: A study of 8 patients who received dexamethasone before the development of COVID-19. We evaluate clinical variables, imaging tests, cytokine release parameters, treatment used and patient evolution.<br />Results: All patients received a 6 mg/day dose with a mean duration of 4.5 days before admission. High resolution computed tomography (HRCT) revealed that most of them presented a severe extension; most patients had a slightly elevated level of cytokine release parameters. Three patients required high-flow oxygen therapy due to respiratory failure; none required orotracheal intubation or died.<br />Conclusion: Dexamethasone in the early stages of SARS-CoV-2 infection appears to be associated with severe COVID-19.<br /> (© 2021 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved.)
Details
- Language :
- Spanish; Castilian
- ISSN :
- 1578-1860
- Volume :
- 221
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Revista clinica espanola
- Publication Type :
- Report
- Accession number :
- 33716310
- Full Text :
- https://doi.org/10.1016/j.rce.2021.02.001